These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35959505)

  • 21. Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis.
    Marshall LZ; Espinosa R; Starner CI; Gleason PP
    J Manag Care Spec Pharm; 2023 Jun; 29(6):599-606. PubMed ID: 37276039
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One
    Goralski JL; Hoppe JE; Mall MA; McColley SA; McKone E; Ramsey B; Rayment JH; Robinson P; Stehling F; Taylor-Cousar JL; Tullis E; Ahluwalia N; Chin A; Chu C; Lu M; Niu T; Weinstock T; Ratjen F; Rosenfeld M
    Am J Respir Crit Care Med; 2023 Jul; 208(1):59-67. PubMed ID: 36921081
    [No Abstract]   [Full Text] [Related]  

  • 23. The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series.
    Ragan H; Autry E; Bomersback T; Hewlett J; Kormelink L; Safirstein J; Shanley L; Lubsch L
    Pediatr Pulmonol; 2022 Feb; 57(2):411-417. PubMed ID: 34850610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with Phe508del mutation: Evidence from randomized controlled trials.
    He R; Lin F; Deng Z; Yu B
    SAGE Open Med; 2024; 12():20503121231225874. PubMed ID: 38249954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI.
    Streibel C; Willers CC; Pusterla O; Bauman G; Stranzinger E; Brabandt B; Bieri O; Curdy M; Bullo M; Frauchiger BS; Korten I; Krüger L; Casaulta C; Ratjen F; Latzin P; Kieninger E
    J Cyst Fibros; 2023 Jul; 22(4):615-622. PubMed ID: 36635199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S945L-CFTR molecular dynamics, functional characterization and tezacaftor/ivacaftor efficacy
    Allan KM; Astore MA; Fawcett LK; Wong SL; Chen PC; Griffith R; Jaffe A; Kuyucak S; Waters SA
    Front Pediatr; 2022; 10():1062766. PubMed ID: 36467478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CFTR Modulators: Current Status and Evolving Knowledge.
    Regard L; Martin C; Da Silva J; Burgel PR
    Semin Respir Crit Care Med; 2023 Apr; 44(2):186-195. PubMed ID: 36535667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural changes in lung morphology detected by MRI after modulating therapy with elexacaftor/tezacaftor/ivacaftor in adolescent and adult patients with cystic fibrosis.
    Fainardi V; Skenderaj K; Ciuni A; Milanese G; Deolmi M; Longo F; Spaggiari C; Sverzellati N; Esposito S; Pisi G
    Respir Med; 2023 Sep; 216():107328. PubMed ID: 37321310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients.
    Doligalski CT; McKinzie CJ; Yang A; Lobo LJ; Coakley R
    Pharmacotherapy; 2022 Jul; 42(7):580-584. PubMed ID: 35689451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients' Plasma by a Novel LC-MS/MS Method.
    Pigliasco F; Cafaro A; Stella M; Baiardi G; Barco S; Pedemonte N; D'Orsi C; Cresta F; Casciaro R; Castellani C; Calevo MG; Mattioli F; Cangemi G
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis Treated with Elexacaftor-Tezacaftor-Ivacaftor.
    Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
    medRxiv; 2023 Nov; ():. PubMed ID: 37645804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor.
    Tümmler B
    Front Pharmacol; 2023; 14():1158207. PubMed ID: 37025483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved glucose tolerance after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis.
    Steinack C; Ernst M; Beuschlein F; Hage R; Roeder M; Schuurmans MM; Schmid C; Gaisl T
    J Cyst Fibros; 2023 Jul; 22(4):722-729. PubMed ID: 36669960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects of ELX/TEZ/IVA on organ-specific CFTR function in two patients with the rare CFTR splice mutations c.273+1G>A and c.165-2A>G.
    Pallenberg ST; Held I; Dopfer C; Minso R; Nietert MM; Hansen G; Tümmler B; Dittrich AM
    Front Pharmacol; 2023; 14():1153656. PubMed ID: 37050906
    [No Abstract]   [Full Text] [Related]  

  • 35. Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators.
    Muilwijk D; Bierlaagh M; van Mourik P; Kraaijkamp J; van der Meer R; van den Bor R; Heijerman H; Eijkemans R; Beekman J; van der Ent K
    J Pers Med; 2021 Dec; 11(12):. PubMed ID: 34945848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis.
    Bihler H; Sivachenko A; Millen L; Bhatt P; Patel AT; Chin J; Bailey V; Musisi I; LaPan A; Allaire NE; Conte J; Simon NR; Magaret AS; Raraigh KS; Cutting GR; Skach WR; Bridges RJ; Thomas PJ; Mense M
    J Cyst Fibros; 2024 Feb; ():. PubMed ID: 38388235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome.
    Pallenberg ST; Pust MM; Rosenboom I; Hansen G; Wiehlmann L; Dittrich AM; Tümmler B
    Microbiol Spectr; 2022 Oct; 10(5):e0145422. PubMed ID: 36154176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor.
    Gómez-Ganda L; Galván-Blasco P; Fernández-Polo A; Cardona V; García-Palop B; Parramón-Teixidó CJ; Polverino E; Álvarez-Fernández A
    Front Pharmacol; 2024; 15():1392986. PubMed ID: 38933680
    [No Abstract]   [Full Text] [Related]  

  • 39. Rescue of chloride and bicarbonate transport by elexacaftor-ivacaftor-tezacaftor in organoid-derived CF intestinal and cholangiocyte monolayers.
    Bijvelds MJC; Roos FJM; Meijsen KF; Roest HP; Verstegen MMA; Janssens HM; van der Laan LJW; de Jonge HR
    J Cyst Fibros; 2022 May; 21(3):537-543. PubMed ID: 34922851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.